The HFE protein (Homeostatic Iron Regulator) is a membrane protein that plays a critical role in systemic iron metabolism. Mutations cause hereditary hemochromatosis and are associated with increased risk of neurodegenerative diseases due to iron accumulation in the brain.
| Protein Name | Homeostatic Iron Regulator (HFE) |
|---|
| Gene | HFE |
|---|
| UniProt ID | Q30201 |
|---|
| Molecular Weight | ~40 kDa |
|---|
| Subcellular Localization | Cell membrane, Endoplasmic reticulum |
|---|
| Protein Family | MHC class I family |
|---|
The HFE protein (Homeostatic Iron Regulator) is a 348-amino acid transmembrane protein that functions as a key regulator of iron homeostasis in the body[^1]. Initially discovered as the protein defective in hereditary hemochromatosis, HFE has since been implicated in neurodegenerative diseases through its effects on brain iron metabolism[^2]. The protein is structurally related to major histocompatibility complex (MHC) class I molecules but does not present antigens; instead, it functions in iron sensing and regulation[^3].
¶ Domain Architecture
| Domain |
Description |
Function |
| Alpha-1 domain |
N-terminal extracellular |
Protein-protein interactions |
| Alpha-2 domain |
Extracellular |
Ligand binding |
| Alpha-3 domain |
Extracellular |
Binds beta-2-microglobulin |
| Transmembrane domain |
Single helix |
Membrane anchoring |
| Cytoplasmic tail |
Intracellular |
Intracellular signaling |
- MHC-like fold: HFE shares the characteristic MHC class I three-domain structure.
- Beta-2-microglobulin binding: Required for proper folding and cell surface expression.
- Transferrin receptor interaction site: The alpha-1 and alpha-2 domains mediate binding to TfR1.
- Cysteine residues: Form disulfide bonds important for structural stability.
- N-linked glycosylation: Multiple sites for carbohydrate attachment.
- Palmitoylation: May affect membrane localization.
- Phosphorylation: Potential regulatory sites.
- Iron sensing: HFE monitors body iron status through interaction with transferrin receptor 1 (TfR1) on cell surfaces.
- Hepcidin regulation: HFE is essential for appropriate hepcidin expression in response to body iron levels.
- Intestinal absorption: By controlling hepcidin, HFE regulates dietary iron uptake in the duodenum.
- Cellular iron uptake: Modulates transferrin-mediated iron uptake via TfR1.
- High expression: Liver, small intestine (duodenum), spleen, heart.
- Moderate expression: Brain (neurons, microglia, endothelial cells).
- Cellular localization: Primarily plasma membrane and endoplasmic reticulum.
Mutations in HFE cause the most common form of hereditary hemochromatosis (type 1):
- C282Y mutation: Most common pathogenic variant; disrupts disulfide bond, prevents proper folding.
- H63D mutation: Mild functional impairment; incomplete penetrance.
- S65C mutation: Rare; mild functional effect.
- Iron accumulation: Elevated iron in AD brain regions (hippocampus, basal ganglia).
- Mechanisms: Iron promotes amyloid-beta aggregation, oxidative stress, neuronal death.
- Evidence: HFE variants associated with increased AD risk in some populations[^4].
- Substantia nigra: Iron accumulation is a hallmark of PD pathology.
- Dopaminergic neurons: Particularly vulnerable to iron-induced oxidative damage.
- HFE variants: May modify PD onset age and severity[^5].
- Amyotrophic Lateral Sclerosis: Iron dysregulation in motor neurons.
- Multiple System Atrophy: Iron accumulation in putamen and cerebellum.
- NBIA: Iron accumulation disorders.
- Oxidative stress: Iron catalyzes Fenton reactions, generating reactive oxygen species.
- Protein aggregation: Iron promotes aggregation of amyloid-beta, alpha-synuclein, tau.
- Mitochondrial dysfunction: Iron accumulation impairs mitochondrial function.
- Inflammation: Iron activates microglia and promotes neuroinflammation.
- ** Ferroptosis**: Iron-dependent programmed cell death pathway.
| Drug |
Route |
BBB Penetration |
Clinical Use |
| Deferoxamine |
IV/SC |
Limited |
FDA approved |
| Deferasirox |
Oral |
Moderate |
FDA approved |
| Deferiprone |
Oral |
Good |
Trials for PD/AD |
- HFE gene therapy: AAV-mediated delivery.
- Hepcidin modulators: Therapeutic targeting of the HFE-hepcidin pathway.
- Antioxidants: Neuroprotective strategies.
- Ferroptosis inhibitors: Liproxstatin-1, ferrostatin-1.
- Hfe knockout mice: Spontaneous iron accumulation; useful for studying iron's role in neurodegeneration.
- Hfe/APP double transgenic: Synergistic effects on amyloid pathology and oxidative stress.
- Hfe/alpha-synuclein models: Investigate iron in synucleinopathies.
- Feder JN, et al. (1996). "A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis." Nat Genet. PMID:8780523
- Pietrangelo A. (2010). "Hereditary hemochromatosis: pathogenesis, diagnosis, and therapy." Gastroenterology. PMID:20153498
- Nandar W, Connor JR. (2011). "HFE gene variants affect iron in the brain." J Nutr. PMID:21957135
- Müller-Lehn CS, et al. (2023). "HFE variants and Alzheimer's disease risk." Neurology. PMID:36758471
- Wang J, et al. (2022). "Iron metabolism in neurodegenerative diseases." Neural Regen Res. PMID:34522664
-
- 1 Feder JN, et al. (1996). A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. PMID:8780523.
- 2 Nandar W, Connor JR. (2011). HFE gene variants affect iron in the brain. J Nutr. PMID:21957135.
- 3 Pietrangelo A. (2010). Hereditary hemochromatosis: pathogenesis, diagnosis, and therapy. Gastroenterology. PMID:20153498.
- 4 Müller-Lehn CS, et al. (2023). HFE variants and Alzheimer's disease risk. Neurology. PMID:36758471.
- 5 Wang J, et al. (2022). Iron metabolism in neurodegenerative diseases. Neural Regen Res. PMID:34522664.
-